Seagen Inc.
Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors

Last updated: 8 Dec 2021

Abstract:

This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.

Status:

Grant

Type:

Utility

Filling date:

8 Jun 2017

Issue date:

7 Dec 2021

Full patent description

Patent application document